NOT FOR DISTRIBUTION
Header cover image

Market Cap

UK£754.2m

Last Updated

2021/05/17 18:16 UTC

Data Sources

Company Financials +

Executive Summary

Uniphar plc operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, and internationally. More Details


Snowflake Analysis

Proven track record with adequate balance sheet.


Similar Companies

Share Price & News

How has Uniphar's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: UPR is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: UPR's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

1.2%

UPR

4.4%

GB Healthcare

0.2%

GB Market


1 Year Return

119.3%

UPR

50.5%

GB Healthcare

22.8%

GB Market

Return vs Industry: UPR exceeded the UK Healthcare industry which returned 54.6% over the past year.

Return vs Market: UPR exceeded the UK Market which returned 23.3% over the past year.


Shareholder returns

UPRIndustryMarket
7 Day1.2%4.4%0.2%
30 Day17.0%5.7%0.1%
90 Day15.2%14.6%5.1%
1 Year120.5%119.3%52.6%50.5%28.3%22.8%
3 Yearn/a-10.0%-14.4%9.4%-3.1%
5 Yearn/a-15.1%-21.1%47.0%19.3%

Long-Term Price Volatility Vs. Market

How volatile is Uniphar's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Uniphar undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: UPR (£2.62) is trading below our estimate of fair value (£8.78)

Significantly Below Fair Value: UPR is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: UPR is good value based on its PE Ratio (30.3x) compared to the UK Healthcare industry average (40.9x).

PE vs Market: UPR is poor value based on its PE Ratio (30.3x) compared to the UK market (25.6x).


Price to Earnings Growth Ratio

PEG Ratio: UPR is poor value based on its PEG Ratio (2x)


Price to Book Ratio

PB vs Industry: UPR is overvalued based on its PB Ratio (4.3x) compared to the GB Healthcare industry average (2.1x).


Future Growth

How is Uniphar forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

14.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: UPR's forecast earnings growth (14.9% per year) is above the savings rate (0.9%).

Earnings vs Market: UPR's earnings (14.9% per year) are forecast to grow slower than the UK market (17.6% per year).

High Growth Earnings: UPR's earnings are forecast to grow, but not significantly.

Revenue vs Market: UPR's revenue (3.8% per year) is forecast to grow slower than the UK market (5.3% per year).

High Growth Revenue: UPR's revenue (3.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: UPR's Return on Equity is forecast to be low in 3 years time (17.8%).


Past Performance

How has Uniphar performed over the past 5 years?

33.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: UPR has high quality earnings.

Growing Profit Margin: UPR's current net profit margins (1.5%) are higher than last year (1.3%).


Past Earnings Growth Analysis

Earnings Trend: UPR's earnings have grown significantly by 33.6% per year over the past 5 years.

Accelerating Growth: UPR's earnings growth over the past year (32.2%) is below its 5-year average (33.6% per year).

Earnings vs Industry: UPR earnings growth over the past year (32.2%) exceeded the Healthcare industry 1.3%.


Return on Equity

High ROE: UPR's Return on Equity (13.7%) is considered low.


Financial Health

How is Uniphar's financial position?


Financial Position Analysis

Short Term Liabilities: UPR's short term assets (€306.6M) do not cover its short term liabilities (€348.8M).

Long Term Liabilities: UPR's short term assets (€306.6M) exceed its long term liabilities (€289.2M).


Debt to Equity History and Analysis

Debt Level: UPR's debt to equity ratio (48.4%) is considered high.

Reducing Debt: UPR had negative shareholder equity 5 years ago, but is now positive and has therefore improved.

Debt Coverage: UPR's debt is well covered by operating cash flow (67.4%).

Interest Coverage: UPR's interest payments on its debt are well covered by EBIT (8x coverage).


Balance Sheet


Dividend

What is Uniphar current dividend yield, its reliability and sustainability?

0.48%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: UPR's dividend (0.48%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.36%).

High Dividend: UPR's dividend (0.48%) is low compared to the top 25% of dividend payers in the UK market (4.1%).


Stability and Growth of Payments

Stable Dividend: UPR is not paying a notable dividend for the UK market, therefore no need to check if payments are stable.

Growing Dividend: UPR is not paying a notable dividend for the UK market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: UPR is not paying a notable dividend for the UK market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of UPR's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.3yrs

Average management tenure


CEO

Ger Rabbette

11.17yrs

Tenure

€1,118,000

Compensation

Mr. Gerard Rabbette B.Comm FCA serves as the Chief Executive Officer of Uniphar Plc. Mr. Rabbette served as the Managing Director of Movianto and Head of Celesio Manufacturing Solutions for Ireland since 2...


CEO Compensation Analysis

Compensation vs Market: Ger's total compensation ($USD1.36M) is above average for companies of similar size in the UK market ($USD955.48K).

Compensation vs Earnings: Insufficient data to compare Ger's compensation with company performance.


Leadership Team

Experienced Management: UPR's management team is seasoned and experienced (7.3 years average tenure).


Board Members

Experienced Board: UPR's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: UPR insiders have bought and sold the same number of shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Uniphar plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Uniphar plc
  • Ticker: UPR
  • Exchange: AIM
  • Founded: 1967
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: €876.379m
  • Listing Market Cap: €754.208m
  • Shares outstanding: 273.02m
  • Website: https://www.uniphar.ie

Number of Employees


Location

  • Uniphar plc
  • 4045 Kingswood Road
  • Citywest Business Park
  • Dublin
  • Co. Dublin
  • D24 V06K
  • Ireland

Listings


Biography

Uniphar plc operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, and internationally. The company operates through three divisions: Commercial & Clinical, P...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/17 18:16
End of Day Share Price2021/05/14 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.